Patients who achieved low disease activity with Xelianz (tofacitinib) extended release 11 mg once daily plus methotrexate after a 24-week open-label run-in period, were randomised to evaluate the efficacy and safety of Xelianz XR 11 mg QD as monotherapy after MTX withdrawal compared with Xelianz XR with continued MTX.
The study demonstrated non-inferiority of MTX withdrawal with Xelianz XR 11 mg QD compared to Xelianz XR 11 mg QD plus MTX at week 48 as measured by the primary endpoint, the change in the Disease Activity Score (DAS28-4[ESR]) from randomization at week 24 to the end of the double-blind MTX withdrawal phase at week 48.
The study results will be presented during a late-breaking oral session at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain (15 June).
For the primary efficacy analysis, patients who achieved Clinical Disease Activity Index low disease activity at week 24 were randomized into the MTX withdrawal phase resulting in least squares mean changes in DAS28-4(ESR) from weeks 24 to 48 of 0.33 and 0.03 in the Xelianz XR monotherapy and Xelianz XR plus MTX groups, respectively [LS mean difference = 0.3; 95% CI, 0.12-0.48; non-inferiority p
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins